Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, has entered into a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC® in Israel. GelrinC is Regentis' proprietary implant for repairing damaged knee cartilage and has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States. The agreement grants AMI exclusive rights to distribute GelrinC in Israel and includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027.
The significance of this announcement lies in its potential to accelerate Regentis' commercial footprint in a key market and provide a template for future distribution partnerships. AMI will leverage its established relationships with orthopedic surgeons, hospitals and clinics to support the product's commercial introduction. The companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance. This agreement supports Regentis' broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate cartilage in a controlled and synchronous process. It aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The Israel agreement represents a strategic move to generate early revenue while the company pursues U.S. regulatory approval.
For investors, the deal provides clarity on Regentis' path to market and demonstrates confidence from a regional distributor. The minimum purchase requirements suggest a committed partner, and the expected 2027 revenue timeline aligns with the company's broader commercialization roadmap. As Regentis continues to advance its Phase 3 program, successful commercialization in Israel and Europe could serve as a proof point for the U.S. market. The full press release can be viewed at https://ibn.fm/t1dw4. For more information on Regentis, visit its newsroom at https//ibn.fm/RGNT. The announcement was disseminated through MissionIR, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides services such as InvestorWire distribution and editorial syndication to 5,000+ outlets.
